C-08 Avastin Trial Didn't Meet Primary Goal

When Avastin® (bevacizumab) was added to standard chemotherapy after surgery, it didn’t reduce the risk that early stage colon cancer would return, according to a press release this morning from Genentech. NSABP C-08 randomly assigned patients with stage II or III colon cancer to FOLFOX chemotherapy with or without additional Avastin.  During the Phase III clinical trial, all patients…  Read More

Continuing Avastin Beyond Initial Cancer Progression Improves Survival Time

Continuing Avastin® (bevacizumab) beyond the time when advanced colorectal cancer gets worse helps patients, according to new study reports.  Patients who continued to receive Avastin with a new chemotherapy regimen after their cancer first progressed lived almost 12 months longer than patients who got more chemo but stopped Avastin.  Both groups did better than those who…  Read More